Truist Securities Reiterates Buy on Amneal Pharmaceuticals, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Les Sulewski has reiterated a Buy rating on Amneal Pharmaceuticals (NASDAQ:AMRX) and raised the price target from $7 to $9.
May 06, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated a Buy rating on Amneal Pharmaceuticals and increased the price target from $7 to $9.
The reiteration of a Buy rating combined with an increased price target typically signals a strong positive outlook on the stock from the analyst. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100